Chloe Atreya
Affiliations: | 2008-2011 | Cellular and Molecular Pharmacology | University of California, San Francisco, San Francisco, CA |
Google:
"Chloe Atreya"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Ruiz-Saenz A, Atreya CE, Wang C, et al. (2023) A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF colorectal tumors. Nature Cancer |
| Fidelman N, Atreya CE, Griffith M, et al. (2022) Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with Y resin microspheres for chemo-refractory colorectal liver metastases. Bmc Cancer. 22: 1307 |
| Kopetz S, Guthrie KA, Morris VK, et al. (2020) Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2001994 |
| Dasari A, Morris VK, Allegra CJ, et al. (2020) ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nature Reviews. Clinical Oncology |
| Middleton G, Yang Y, Campbell CD, et al. (2020) BRAF-mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Fidelman N, Atreya C, Griffith M, et al. (2020) 3:54 PM Abstract No. 243 Phase I Prospective Trial of TAS-102 (trifluride and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases Journal of Vascular and Interventional Radiology. 31: S109 |
| Savoie M, Paciorek A, Van Blarigan E, et al. (2020) 006 Sexual Function in Women after Treatment for Colorectal Cancer and Anal Cancer The Journal of Sexual Medicine. 17: S221 |
| Le D, Kavan P, Kim T, et al. (2018) Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability-high (MSI-H) colorectal cancer: KEYNOTE-164. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: v107 |
| Ursem C, Atreya CE, Van Loon K. (2018) Emerging treatment options for -mutant colorectal cancer. Gastrointestinal Cancer : Targets and Therapy. 8: 13-23 |
| Corcoran RB, Andre T, Atreya CE, et al. (2018) Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. Cancer Discovery |